Death prompts clinical hold for Innate's lacutamab IND

5 October 2023

Innate Pharma (Euronext Paris: IPH) was trading 15% lower by late-activity in Paris Thursday.

The French biotech company earlier announced that the US Food and Drug Administration (FDA) had placed a partial clinical hold on the lacutamab investigational new drug (IND).

"We do not currently anticipate any delay for the TELLOMAK Phase II final data, due shortly"Lacutamab is an anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical development for rare cutaneous lymphomas of T lymphocytes, which have a poor prognosis, with few efficacious and safe therapeutic options at advanced stages.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK